| (Values in U.S. Thousands) | Dec, 2016 | Dec, 2015 | Dec, 2014 | Dec, 2013 | Dec, 2012 |
| Sales | 80 | 120 | 90 | 20 | 0 |
| Sales Growth | -33.33% | +33.33% | +350.01% | unch | unch |
| Net Income | -11,580 | -11,700 | -11,060 | -8,820 | -6,710 |
| Net Income Growth | +1.03% | -5.79% | -25.40% | -31.45% | unch |
Biostage Inc (BSTGD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Biostage, Inc. is a biotechnology company. It is engaged in developing bioengineered organ implants based on the company's new Cellframe (TM) technology to treat life-threatening conditions of the esophagus, trachea or bronchus. Biostage Inc., formerly known as Harvard Apparatus Regenerative Technology Inc., is based in HOLLISTON, Mass.